Metahexamide

This classification denotes an anti-diabetic agent with the molecular formula C14H21N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) T3U6F5D722, chemically known as 1,3,5-triazine-2,4-diamine, 6-chloro-n,n,n,n-tetraethyl- but more generally known as metahexamide, which bears US NIH Compound Identifier 11259. European Medicines Agency schedules Metahexamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08803MIG. The term METAHEXAMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4) WHO schedules metahexamide in its Anatomical Therapeutic Chemical (ATC) Classification. METAHEXAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule metahexamide under HS 29350090 and SITC 51580. As of Q4 2014, METAHEXAMIDE remains US FDA's Preferred Term for this commodity. Metahexamide bears US NLM identifiers UMLS ID C0663351 and NCI Concept Code C91022. SMILES: S(=O)(=O)(NC(=O)NC1CCCCC1)C1CC(N)C(CC1)C.